Letters Dipeptidyl peptidase-4 inhibitors, sulphonylureas, and hypoglycaemia

Authors’ reply to Tufan and colleagues and Boucaud-Maitre

BMJ 2016; 353 doi: https://doi.org/10.1136/bmj.i3188 (Published 07 June 2016) Cite this as: BMJ 2016;353:i3188
  1. Francesco Salvo, clinical pharmacologist1 2 3,
  2. Nicholas Moore, professor of pharmacology1 2 3 4,
  3. Mickael Arnaud, statistician1 2,
  4. Philip Robinson, medical writer4 5,
  5. Emanuel Raschi, assistant professor of pharmacology6,
  6. Fabrizio De Ponti, professor of pharmacology6,
  7. Bernard Bégaud, professor of pharmacology1 2 3,
  8. Antoine Pariente, professor of pharmacology1 2 3
  1. 1University of Bordeaux, UMR1219, F-33000 Bordeaux, France
  2. 2INSERM, UMR1219, Bordeaux Population Health Research Centre, Pharmacoepidemiology team, Bordeaux, France
  3. 3CHU Bordeaux, Bordeaux, France
  4. 4CIC Bordeaux CIC1401, Bordeaux, France
  5. 5ADERA, Pessac, France
  6. 6Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
  1. francesco.salvo{at}u-bordeaux.fr

In response to Tufan and colleagues, it is true that older frail patients are under-represented in our meta-analysis, but such patients are under-represented in clinical trials in general, not just those investigating type 2 diabetes.1 2 Even when there is no formal age limit, the common exclusion of patients with organ dysfunction and comorbidities means that most older people are excluded.3 We can but hope that further trials will provide more information on benefits and risks of drugs in older people and will update …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe